Real-world tirzepatide vs semaglutide in non-diabetic obesity
However, these metabolic benefits are often counterbalanced by complications such as hypoglycemia, stemming from mechanisms like altered nutrient absorption, exaggerated insulin responses, and increased incretin secretion [16, 17]
But 'very weak' isn't 'zero.' At very high, supra-physiological doses not typically used in responsible research, some minor, transient elevations might be observed
The objective of the trial was to demonstrate that use of this other insulin glargine product could significantly lower the risk of major cardiovascular outcomes compared to standard care
Once inside the mitochondrial matrix, carnitine palmitoyltransferase II (CPT II) converts fatty acyl-carnitine back into fatty acyl-CoA, allowing beta-oxidation to proceed in experimental systems
And what I'm teaching in that course is what I teach clinicians and I train clinicians